The National Institute of Neurological Disorders and Stroke (NINDS) encourages grant applications for research on the shared neurobiology of fragile X syndrome and autism.
This announcement is made together with 2 other components of the National Institutes of Health (NIH), the Canadian Institutes of Health Research (CIHR), the Health Research Board (HRB) of Ireland, the FRAXA Research Foundation, Cure Autism Now (CAN), the National Alliance for Autism Research (NAAR), and Autism Speaks, and is supported by 2 funding mechanisms: R03 and R21.
Fragile X syndrome is the most common inherited form of mental retardation. Autism is a complex neurodevelopmental disorder with early childhood onset. Between 2.5 percent and 6 percent of autistic individuals have fragile X syndrome, and approximately 25 percent of children with fragile X have autism. Applications in response to this initiative should focus on a topic related to understanding neural pathways, circuits, systems, and molecules that play a role in the cause or pathophysiology of fragile X syndrome and may be implicated in autism.
For more information, potential applicants should contact Dr. Laura Mamounas, Program Director, Neurogenetics Cluster, NINDS; telephone: 301-496-5745; e-mail: email@example.com. For a more detailed description of this announcement, visit http://grants.nih.gov/grants/guide/pa-files/PA-06-429.html (R03) or http://grants.nih.gov/grants/guide/pa-files/PA-06-430.html (R21).